Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 9, 2020HaematologicaOpen Access

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMarie José KerstenLymphoma Study AssociationJDJulia DriessenAmsterdam University Medical CentersJZJosée M. ZijlstraAmsterdam Neuroscience

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kersten et al. (2020) studied this question.

synapsesocial.com/papers/69ffc679b124fe5819859cefhttps://doi.org/10.3324/haematol.2019.243238
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes2008 · 2,122 citations
  2. 2Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?2018 · 134 citations
  3. 3Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,739 citations
  4. 4CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy1995 · 445 citations
  5. 5Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma2017 · 324 citations